The Supreme Court has reestablished access to mifepristone across the nation with a temporary ruling that permits women in all 50 states to receive the medication by mail. Since its FDA approval in 2000, mifepristone has been utilized in over five million abortions in the US and boasts a better safety record than many common antibiotics. This decision reverses a previous lower court limitation. The Court is set to hear comprehensive arguments later this term. This ruling has important implications for women, healthcare providers, and the upcoming political confrontations.
